The development and distribution of vaccines have been making headlines amid a surge in COVID-19 cases and this past week was no exception.
Novavax Inc. (NVAX), which was up 74%, was one of the top gainers for the week ending January 29, 2021, thanks to encouraging trial results of its COVID-19 vaccine candidate. In a phase III trial, conducted in UK, the two-dose regimen of Novavax vaccine NVX-CoV2373 has been found to have an efficacy rate of 89.3%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.